CAS 193681-12-8: alamifovir

Alamifovir is an antiviral agent, which is synthetically derived. The mode of action of Alamifovir involves the inhibition of viral replication within host cells by targeting specific viral enzymes crucial for the replication process. This interference with the viral life cycle diminishes the ability of the virus to propagate and spread within the host organism. Alamifovir is primarily used in the treatment of viral infections, potentially offering therapeutic benefits for diseases caused by DNA viruses. Its effectiveness is contingent upon its ability to selectively target viral components with minimal cytotoxic effects on host cells, ensuring a beneficial therapeutic index. The applications of Alamifovir in antiviral therapy highlight its relevance in the continuous search for effective treatments against viral pathogens that pose significant clinical challenges. Research into Alamifovir's pharmacokinetics, safety profile, and resistance patterns is ongoing, with the aim of optimizing its use in clinical settings and expanding its utility across a broader spectrum of viral infections.

Alamifovir: HBV-specific antiviral, purine analog prodrug; active against wild-type/lamivudine-resistant HBV; inhibits DNA initiation/packaging.